Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients

American Journal of Hematology

Volumn 87, Issue 9, 2012, Pages 861-864

  Moulopoulos, Lia A ^a   Dimopoulos, Meletios A ^a   Kastritis, Efstathios ^a   Christoulas, Dimitrios ^a   Gkotzamanidou, Maria ^a   Roussou, Maria ^a   Koureas, Andreas ^a   Migkou, Magdalini ^a   Gavriatopoulou, Maria ^a   Eleutherakis Papaiakovou, Evangelos ^a   Gika, Dimitra ^a   Koutoulidis, Vasilios ^a   Terpos, Evangelos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; BONE MARROW DISEASE; BONE MARROW INFILTRATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CHROMOSOME ADDITION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DIPLOIDY; DRUG RESPONSE; FEMALE; GENETIC DISORDER; HUMAN; HYPODIPLOID; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CHROMOSOME ABERRATIONS; CONTRAST MEDIA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 84865398631     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23258     Document Type: Article

References (17)

1. Dimopoulos MA, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009; 23: 1546-1556.
2. Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and management of myeloma bone disease. J Clin Oncol 2011; 29: 1907-1915.
3. Moulopoulos LA, Dimopoulos MA. Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 1997; 90: 2127-2147.
4. Moulopoulos LA, Gika D, Anagnostopoulos A, et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol 2005; 16: 1824-1828.
5. Moulopoulos LA, Dimopoulos MA, Christoulas D, et al. Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia 2010; 24: 1206-1212.
6. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2. Blood 2011; 117: 4696-4700.
7. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 2004; 64: 1546-1558.
8. Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009; 27: 4585-4590.
9. Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010; 116: e56-e65.
10. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
11. Hastings RJ, Cavani S, Bricarelli FD, et al. Cytogenetic guidelines and quality assurance: A common European framework for quality assessment for constitutional and acquired cytogenetic investigations. Eur J Hum Genet 2007; 15: 525-527.
12. Brothman AR, Persons DL, Shaffer LG. Nomenclature evolution: Changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res 2009; 127: 1-4.
13. Groupe Français de Cytogénétique Hématologique (GFCH). Recommendations for the cytogenetic management of multiple myeloma proposed by the French Group for Cytogenetic Hematology. Pathol Biol (Paris) 2004; 52: 263-264.
14. Hillengass J, Zechmann CM, Nadler A, et al. Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma. Int J Cancer 2008; 122: 2871-2875.
15. Ailawadhi S, Abdelhalim AN, Derby L, et al. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Cancer 2010; 116: 84-92.
16. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications. J Clin Oncol 2007; 25: 1121-1128.
17. Shaughnessy JDJr, Haessler J, van Rhee F, et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: Superiority of molecular genetics. Br J Hematol 2007; 137: 530-536.